⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Curis, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Curis, Inc.
↗Lexington, USA
Curis, Inc. is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. The company emphasizes immuno-oncology and precision oncology, targeting biological pathways that help cancer cells grow, evade the immune system, or resist existing therapies.
Curis conducts its research and development programs both internally and through strategic collaborations, such as its long-standing partnership with Aurigene. The company's pipeline includes clinical-stage candidates targeting hematological malignancies and solid tumors, with a focus on areas of high unmet medical need.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$5M-$10M
Founded:2000
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$202.1M
STOCK
Exchange:NASDAQ
Ticker:CRIS
Market Cap:$0.01B
PIPELINE
Stage:Phase 1/2
Lead Drug Stage:Phase 1/2
Modalities:Small molecule
Active Trials:21
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Aurigene (Discovery and development collaboration), Genentech/Roche (Commercialization of Erivedge)
COMPETITION
Position:Niche Player
Competitors:Jazz Pharmaceuticals, Sana Biotechnology, Kite Pharma, Kymera Therapeutics
LEADERSHIP
Key Executives:
James Dentzer - CEO & President
Jonathan Zung - Chief Development Officer
Diantha Duvall - Chief Financial Officer
LINKS
Website:curis.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Curis, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.